Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Q4 2025 Net Sales: $693 million, a 3.9% increase from Q4 2024. Q4 2025 Gross Margin: 49.8% GAAP, 52.5% non-GAAP. Q4 2025 Operating Loss: $119 million, including $173 million in impairment charges. Q4 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at ...

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

(RTTNews) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025. The company posted ...

Bio-Rad Laboratories missed estimated earnings by -5.28%, reporting an EPS of $2.51 versus an estimate of $2.65. Revenue was up $25.70 million from the same period last year. In the previous quarter, ...

Bio-Rad Laboratories Inc. (BIO) reported its Q4 2025 earnings with an EPS of $2.51, falling short of the forecasted $2.71. The revenue slightly surpassed expectations, coming in at $693.2 million ...